Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 1/2 3Phase NA 2Phase 3 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Carcinoma, Hepatocellular 37Liver Neoplasms 20Neoplasms 17Leukemia, Myeloid, Acute 13Neoplasm Metastasis 11Carcinoma, Renal Cell 9Carcinoma, Non-Small-Cell Lung 9Pancreatic Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Breast Neoplasms 6Brain Neoplasms 6Unspecified Adult Solid Tumor, Protocol Specific 5Prostatic Neoplasms 5Multiple Myeloma 5Lung Neoplasms 5Kidney Neoplasms 5Recurrence 4Glioblastoma 4Colorectal Neoplasms 4Sarcoma 3Rectal Neoplasms 3Myelodysplastic Syndromes 3Leukemia, Promyelocytic, Acute 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Erythroblastic, Acute 3Leukemia, Eosinophilic, Acute 3

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × Sorafenib × Clear all
NCT02298348 2026-03-23

N2013-02

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Active not recruiting
18 enrolled
CNS

Neuroblastoma, Recurrence

NCT01531361 2021-01-22

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

M.D. Anderson Cancer Center

Phase 1 Completed
46 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT01561833 2020-08-13

A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients

Yale University

Phase 1 Completed
12 enrolled 4 charts
Lymphoid

Recurrence, Lymphoma, T-Cell

NCT01683149 2016-03-04

Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
13 enrolled

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡